MedPath

KEYNOTE-B61 Demonstrates Robust Data for Non-Clear Cell Renal Cell Carcinoma Treatment

6 months ago2 min read

Key Insights

  • The KEYNOTE-B61 trial, investigating pembrolizumab plus lenvatinib, shows more robust data than the CA-209 9KU trial for non-clear cell renal cell carcinoma (non-ccRCC).

  • KEYNOTE-B61 enrolled 158 patients with various non-ccRCC subtypes, reporting a median PFS of 18 months, providing more reliable findings due to its larger sample size.

  • While nivolumab plus cabozantinib remains a viable option, KEYNOTE-B61's pembrolizumab plus lenvatinib has emerged as a preferred treatment for many oncologists treating non-ccRCC.

The KEYNOTE-B61 trial, evaluating pembrolizumab (Keytruda) plus lenvatinib (Lenvima), has demonstrated more robust data compared to the CA-209 9KU trial for the treatment of non-clear cell renal cell carcinoma (non-ccRCC). This Phase 2 trial's findings are influencing treatment paradigms for this challenging cancer subtype.

KEYNOTE-B61 Trial Details

The single-arm KEYNOTE-B61 trial enrolled 158 patients with non-ccRCC, encompassing chromophobe (n = 29), papillary (n = 93), and unclassified (n = 21) disease subtypes. The larger sample size and broader representation of histologic subtypes in KEYNOTE-B61 resulted in narrow confidence intervals and relatively reliable findings. The trial reported a median progression-free survival (PFS) of 18 months (95% CI, 14-not reached), with insufficient follow-up data to determine the median overall survival.

CA-209 9KU Trial Context

The CA-209 9KU trial (NCT03635892) was a single-center trial that enrolled 47 patients with non-ccRCC. While the combination investigated in CA-209 9KU, nivolumab (Opdivo) and cabozantinib (Cabometyx), is familiar to many oncologists and may be a first-line treatment choice for patients with clear cell RCC, the strength of evidence from CA-209 9KU is limited due to its noncomparative design and small sample size. Data from rarer non-ccRCC subtypes, such as chromophobe RCC, were not consistently reported in subsequent updates.

Treatment Paradigm

According to Thomas Westbrook, MD, assistant professor, Department of Internal Medicine, Rush University, the KEYNOTE-B61 regimen has emerged as a preferred non-ccRCC treatment option for many oncologists, although nivolumab plus cabozantinib may also be considered. Cross-trial comparisons between CA-209 9KU and KEYNOTE-B61 are unreliable due to differences in the trials’ baseline patient populations. However, the KEYNOTE-B61 regimen has emerged as a preferred non-ccRCC treatment option for many oncologists.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Clinical Trials

Related research and studies

Highlighted Clinical Trials

NCT03635892Active, Not RecruitingPhase 2
Memorial Sloan Kettering Cancer Center
Posted 8/13/2018

Related News

© Copyright 2025. All Rights Reserved by MedPath